ZA201500995B - Low dose pharmaceutical composition - Google Patents

Low dose pharmaceutical composition

Info

Publication number
ZA201500995B
ZA201500995B ZA2015/00995A ZA201500995A ZA201500995B ZA 201500995 B ZA201500995 B ZA 201500995B ZA 2015/00995 A ZA2015/00995 A ZA 2015/00995A ZA 201500995 A ZA201500995 A ZA 201500995A ZA 201500995 B ZA201500995 B ZA 201500995B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical composition
low dose
dose pharmaceutical
low
composition
Prior art date
Application number
ZA2015/00995A
Other languages
English (en)
Inventor
Preeti Raut
Geena Malhotra
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of ZA201500995B publication Critical patent/ZA201500995B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA2015/00995A 2014-02-12 2015-02-12 Low dose pharmaceutical composition ZA201500995B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN495MU2014 IN2014MU00495A (cs) 2014-02-12 2015-02-12

Publications (1)

Publication Number Publication Date
ZA201500995B true ZA201500995B (en) 2015-12-23

Family

ID=52544516

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/00995A ZA201500995B (en) 2014-02-12 2015-02-12 Low dose pharmaceutical composition

Country Status (3)

Country Link
IN (1) IN2014MU00495A (cs)
WO (1) WO2015121649A1 (cs)
ZA (1) ZA201500995B (cs)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018209164B2 (en) 2017-01-17 2021-11-04 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2019008487A1 (en) * 2017-07-05 2019-01-10 Novartis Ag NEW PHARMACEUTICAL COMPOSITION

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2552386T3 (es) * 2009-04-03 2015-11-27 F. Hoffmann-La Roche Ag Composiciones de {3-[5-(4-cloro-fenil)-1H-pirrol[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida del ácido propano-1-sulfónico y usos de las mismas
US20130172375A1 (en) * 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition

Also Published As

Publication number Publication date
WO2015121649A1 (en) 2015-08-20
IN2014MU00495A (cs) 2015-09-25

Similar Documents

Publication Publication Date Title
ZA201605300B (en) Pharmaceutical compositions comprising azd9291
GB201618482D0 (en) Pharmaceutical compositions
GB201419257D0 (en) Pharmaceutical compositions
GB201409471D0 (en) Pharmaceutical composition
IL249553A0 (en) Pharmaceutical preparations
SG11201605366QA (en) Pharmaceutical composition containing pyridylaminoacetic acidcompound
GB201409488D0 (en) Pharmaceutical composition
GB201409485D0 (en) Pharmaceutical composition
RS59626B1 (sr) Farmaceutska kompozicija koja sadrži mirabegron
GB201521462D0 (en) Pharmaceutical composition
GB201506526D0 (en) Medicinal composition
ZA201502073B (en) Pharmaceutical composition
IL250817A0 (en) pharmaceutical preparations
ZA201508726B (en) Pharmaceutical composition
PT3200772T (pt) Composições farmacêuticas compreendendo alpelisib
GB201515310D0 (en) Pharmaceutical composition
GB201520862D0 (en) Pharmaceutical composition
PT3089740T (pt) Composição farmacêutica
ZA201500995B (en) Low dose pharmaceutical composition
SG10201504332VA (en) Pharmaceutical Composition
SG11201608123VA (en) Pharmaceutical composition for external use
SG11201608124XA (en) Pharmaceutical composition for external use
GB201521456D0 (en) Pharmaceutical composition
SG11201608122PA (en) Pharmaceutical composition for external use
SG2014014872A (en) Pharmaceutical compositions